Literature DB >> 27865874

Bromodomain-containing protein 2 induces insulin resistance via the mTOR/Akt signaling pathway and an inflammatory response in adipose tissue.

Ruixin Sun1, Yi Wu1, Weihua Hou1, Zujun Sun1, Yuxiong Wang1, Huanhuan Wei1, Wei Mo1, Min Yu2.   

Abstract

Insulin resistance is a major metabolic abnormality in a large majority of patients with type II diabetes. Bromodomain-containing protein 2 (Brd2), a transcriptional co-activator/co-repressor with switch mating type/sucrose non-fermenting (SWI/SNF)-like functions that regulates chromatin, suppresses adipocyte differentiation and regulates pancreatic β-cell biology. However, the effects of Brd2 on insulin resistance remain unknown. Here, overexpression of Brd2 in white adipose tissue of wild-type (WT) mice led to insulin resistance. Brd2 overexpression induced the expression of nuclear Factor-κΒ (NF-κΒ) target genes, mainly involving proinflammatory and chemotactic factors, in adipocytes. Furthermore, it decreased the expression of DEP domain containing mTOR-interacting protein (Deptor) to enhance mechanistic target of rapamycin (mTOR) signaling, thus blocking insulin signaling. Collectively, these results provided evidence for a novel role of Brd2 in chronic inflammation and insulin resistance, suggesting its potential in improving insulin resistance and treating metabolic disorders.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brd2; Inflammation; Insulin resistance; Insulin signaling pathway; mTOR signaling

Mesh:

Substances:

Year:  2016        PMID: 27865874     DOI: 10.1016/j.cellsig.2016.11.011

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  8 in total

1.  Gene Networks of Hyperglycemia, Diabetic Complications, and Human Proteins Targeted by SARS-CoV-2: What Is the Molecular Basis for Comorbidity?

Authors:  Olga V Saik; Vadim V Klimontov
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

2.  Epigenetic Reader Bromodomain Containing Protein 2 Facilitates Pathological Cardiac Hypertrophy via Regulating the Expression of Citrate Cycle Genes.

Authors:  Zhirong Lin; Zhenzhen Li; Zhen Guo; Yanjun Cao; Jingyan Li; Peiqing Liu; Zhuoming Li
Journal:  Front Pharmacol       Date:  2022-05-25       Impact factor: 5.988

3.  Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors.

Authors:  K E Lines; M Stevenson; P Filippakopoulos; S Müller; H E Lockstone; B Wright; S Grozinsky-Glasberg; A B Grossman; S Knapp; D Buck; C Bountra; R V Thakker
Journal:  Oncogenesis       Date:  2017-05-15       Impact factor: 7.485

Review 4.  mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases.

Authors:  Hannah E Walters; Lynne S Cox
Journal:  Int J Mol Sci       Date:  2018-08-08       Impact factor: 5.923

Review 5.  The BET family in immunity and disease.

Authors:  Nian Wang; Runliu Wu; Daolin Tang; Rui Kang
Journal:  Signal Transduct Target Ther       Date:  2021-01-19

Review 6.  A Comprehensive Review of BET Protein Biochemistry, Physiology, and Pathological Roles.

Authors:  Hafiz Akbar Ali; Yalan Li; Akram Hafiz Muhammad Bilal; Tingting Qin; Ziqiao Yuan; Wen Zhao
Journal:  Front Pharmacol       Date:  2022-03-25       Impact factor: 5.810

Review 7.  Roles of Bromodomain Extra Terminal Proteins in Metabolic Signaling and Diseases.

Authors:  Dayu Wu; Qiong Duan
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-22

8.  Adipose tissue and age‑dependent insulin resistance: New insights into WAT browning (Review).

Authors:  Chuanlong Wu; Pei Yu; Ruixin Sun
Journal:  Int J Mol Med       Date:  2021-03-11       Impact factor: 4.101

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.